Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25125561 | 1.00 | PDK1 (0.39) | PDK1PDK2PDK3CA12CA1 | |
| Hydrochloric Acid SCHEMBL31393754 | 0.96 | PDK1 (0.37) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL9801150 | 0.83 | PDK1 (0.37) | PDK1PDK2PDK3GAA | |
| SCHEMBL772683 | 0.83 | PDK1 (0.37) | PDK1PDK2PDK3 | |
| SCHEMBL17778486 | 0.83 | PDK1 (0.51) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL1700062 | 0.83 | PDK1 (0.51) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL24630698 | 0.83 | PDK1 (0.51) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL1806182 | 0.83 | PDK1 (0.37) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL24624661 | 0.80 | PDK1 (0.36) | PDK1PDK2PDK3PIK3CAMTOR | |
| SCHEMBL18483388 | 0.80 | PDK1 (0.55) | PDK1PDK2PDK3MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112479459-B | Preparation method of preferential water permeable membrane, morpholine wastewater treatment method and morpholine substance recovery method | 万华化学集团股份有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-112479459-A | Preparation method of preferential water permeable membrane, morpholine wastewater treatment method and morpholine substance recovery method | 万华化学集团股份有限公司 | 2021-03-12 | — | — | CN | claimed |
| EP-2197933-B1 | AMINE CATALYSTS FOR POLYURETHANE FOAMS | HONEYWELL INT INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250154162-A1 | COMPOUND FOR REGULATING AND CONTROLLING 15-PGDH ACTIVITY AND PREPARATION METHOD THEREFOR | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118591545-A | Compound for regulating 15-PGDH activity and preparation method thereof | 赛诺哈勃药业（成都）有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| CN-118382612-A | Method for producing blocked isocyanate compound and method for producing isocyanate compound | 旭化成株式会社 | 2024-07-23 | — | — | CN | disclosed |
| WO-2024063100-A1 | METHOD FOR PRODUCING POLYVALENT CARBODIIMIDE B | 旭化成株式会社 | 2024-03-28 | — | — | WO | disclosed |
| WO-2023143432-A1 | COMPOUND FOR REGULATING AND CONTROLLING 15-PGDH ACTIVITY AND PREPARATION METHOD THEREFOR | 赛诺哈勃药业（成都）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023106377-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | 旭化成株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| EP-1869054-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | Ranbaxy Laboratories Limited (IN) | 2007-12-26 | — | — | EP | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2006085212-A2 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-17 | — | — | WO | disclosed |
| EP-0789062-B1 | WATER-ABSORBENT RESIN DISPERSION AND POLYURETHANE COMPOSITION | SANYO CHEMICAL IND LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5994421-A | CROSSLINKING | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0789062-A1 | WATER-ABSORBENT RESIN DISPERSION AND POLYURETHANE COMPOSITION | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | JAK1, JAK3, MYLK2 | PDK1 286/4885PDK2 491/4885PDK3 364/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | PDK1 3777/4885PDK2 2433/4885PDK3 3371/4885 |
| US-20250154162-A1 | COMPOUND FOR REGULATING AND CONTROLLING 15-PGDH ACTIVITY AND PREPARATION METHOD THEREFOR | CYP51A1, HPGD, HSD11B1 | PDK1 184/4885PDK2 189/4885PDK3 269/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | PDK1 2305/4885PDK2 1125/4885PDK3 2412/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PDK1 323/4885PDK2 554/4885PDK3 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.